Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.30 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.30 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270352 | 0.93 | POLB (0.36) | POLBNT5EABL1RIN1DUT | |
| SCHEMBL2112367 | 0.91 | POLB (0.40) | POLBNT5EABL1RIN1DUT | |
| SCHEMBL618137 | 0.89 | POLB (0.39) | POLBNT5EABL1RIN1DUT | |
| SCHEMBL2113458 | 0.88 | POLB (0.38) | POLBNT5EABL1RIN1DUT | |
| SCHEMBL332974 | 0.88 | POLB (0.49) | POLBNT5EABL1RIN1DUT | |
| SCHEMBL7199260 | 0.86 | POLB (0.41) | POLBNT5EDUTP2RY2P2RY6 | |
| SCHEMBL8607539 | 0.85 | POLB (0.45) | POLBNT5EABL1RIN1ADORA3 | |
| SCHEMBL8389649 | 0.84 | SMN1; SMN2 (0.39) | POLBABL1RIN1 | |
| SCHEMBL2270354 | 0.82 | POLB (0.38) | POLBNT5EABL1RIN1DUT | |
| SCHEMBL2112368 | 0.80 | POLB (0.42) | POLBNT5EABL1RIN1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064769-A1 | INDUCTION OF STEM-LIKE ACTIVATED T CELLS | PHIO PHARMACEUTICALS CORP. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-11926828-B2 | Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1 | PHIO PHARMACEUTICALS CORP. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240035049-A1 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2024-02-01 | — | — | US | disclosed |
| US-20230348939-A1 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | FLAGSHIP LABS, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230272430-A1 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-08-31 | — | — | US | disclosed |
| US-20230242899-A1 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | TESSERA THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2023130021-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED DELIVERY PROPERTIES | PHIO PHARMACEUTICALS CORP. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230089478-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED SYSTEMIC DELIVERY | PHIO PHARMACEUTICALS CORP. (US) | 2023-03-23 | — | — | US | disclosed |
| US-11584933-B2 | RNA interference in ocular indications | PHIO PHARMACEUTICALS CORP. (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2023015264-A1 | IMMUNOTHERAPY OF CANCER UTILIZING NATURAL KILLER CELLS TREATED WITH CHEMICALLY MODIFIED OLIGONUCLEOTIDES | PHIO PHARMACEUTICALS CORP. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20110263680-A1 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | RXI PHARMACEUTICALS CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011119871-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | RXI PHRMACEUTICALS CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119887-A1 | RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119852-A1 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | RXI PHARMACEUTICALS CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110237648-A1 | RNA INTERFERENCE IN SKIN INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2011-09-29 | — | — | US | disclosed |
| EP-2342340-A1 | RNA INTERFERENCE IN SKIN INDICATIONS | Rxi Pharmaceuticals Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2340310-A2 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | Rxi Pharmaceuticals Corporation (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010033247-A2 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | RXI PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010033246-A1 | RNA INTERFERENCE IN SKIN INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584933-B2 | RNA interference in ocular indications | RXRA, RXRB, RXRG | POLB 1737/4885NT5E 1717/4885ABL1 4283/4885 |
| US-11926828-B2 | Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1 | MMP1, MMP3, MMP11 | POLB 56/4885NT5E 212/4885ABL1 3177/4885 |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | POLB 257/4885NT5E 126/4885ABL1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.